profit from every €100 of sales.
€0€100
Genfit
€10.70-1.29% today
+108.6% since Dec 23, 25
1-year low €5.131-year high €14.66
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Genfit sold, what it kept, and what it did with the cash.
Sales went from €20.2 million in 2022 to €65.4 million in 2025, with -€86.0 million of profit last year.
SalesProfit
Genfit vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| Genfit | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Genfit's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 20 | 29 | 67 | 65 | |
| 20 | 28 | 67 | 65 | |
| -27 | -27 | 3 | -54 | |
| -18 | -22 | 8 | -83 | |
| -24 | -29 | 2 | -86 | |
| -0.48 | -0.58 | 0.03 | – | |
| 98.8% | 98.8% | 99.6% | 99.5% | |
| -135.3% | -95.1% | 4.8% | -81.9% | |
| -117.4% | -101.2% | 2.2% | -131.4% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 216 | 174 | 151 | 159 |
| Cash | 136 | 78 | 82 | 101 |
| Total debt | 75 | 70 | 62 | 151 |
| Total liabilities | 121 | 106 | 82 | 182 |
| 95 | 68 | 69 | -23 | |
| 49 | 50 | 50 | – | |
| -8.6% | -13.0% | 3.8% | -49.9% | |
| -25.1% | -42.5% | 2.2% | 381.5% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -73 | -55 | 16 | -26 | |
| – | 2 | 1 | 3 | |
| -73 | -58 | 15 | -30 | |
| Dividends paid | 0 | – | – | – |
| – | – | – | – | |
| 0 | 1 | 1 | 0 |
Valuation
- –
- –
- –
- -19.6×
- 8.2×
- –
- –
- -5.5%
- -16.0%
- –
Profitability
- 99.5%
- -81.9%
- -131.4%
- –
- -49.9%
- -16.9%
- –
- –
- –
- –
Growth
- +48.0%
- –
- –
- –
- −2.8%
Financial health
- –
- -6.69
- –
- -70.7×
- 2.00
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 6%of 952
Bottom 4%of 883
Top 12%of 888
Bottom 17%of 987
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
28No pass
Philip Fisher
52No pass
Peter Lynch
62Pass
Joel Greenblatt
2No pass
Charlie Munger
36No pass
Terry Smith
37No pass
Questions about Genfit
Is Genfit a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Genfit AI analysis
What does Genfit do?
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. It is in Biotechnology, based in Loos, France.
Is Genfit stock halal?
Yes. Genfit passes our halal screen: its business is permitted and its debt is 28% of its market value, under the 30% limit. How we check
Who are Genfit's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Genfit's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.